journal
MENU ▼
Read by QxMD icon Read
search

Antiviral Research

journal
https://www.readbyqxmd.com/read/28641998/construction-of-a-hepatitis-b-virus-neutralizing-chimeric-monoclonal-antibody-recognizing-escape-mutants-of-the-viral-surface-antigen-hbsag
#1
Forough Golsaz-Shirazi, Mohammad Mehdi Amiri, Samira Farid, Motahareh Bahadori, Felix Bohne, Sebastian Altstetter, Lisa Wolff, Tohid Kazemi, Jalal Khoshnoodi, Mohammad Hojjat-Farsangi, Michael Chudy, Mahmood Jeddi-Tehrani, Ulrike Protzer, Fazel Shokri
Hepatitis B virus (HBV) infection is a global burden on the health-care system and is considered as the tenth leading cause of death in the world. Over 248 million patients are currently suffering from chronic HBV infection worldwide and annual mortality rate of this infection is 686000. The "a" determinant is a hydrophilic region present in all antigenic subtypes of hepatitis B surface antigen (HBsAg), and antibodies against this region can neutralize the virus and are protective against all subtypes. We have recently generated a murine anti-HBs monoclonal antibody (4G4), which can neutralize HBV infection in HepaRG cells and recognize most of the escape mutant forms of HBsAg...
June 19, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28633989/efficacy-and-cytotoxicity-in-cell-culture-of-novel-%C3%AE-hydroxytropolone-inhibitors-of-hepatitis-b-virus-ribonuclease-h
#2
Elena Lomonosova, Jil Daw, Aswin K Garimallaprabhakaran, Nana B Agyemang, Yashkumar Ashani, Ryan P Murelli, John E Tavis
Chronic Hepatitis B virus (HBV) infection is a major worldwide public health problem. Current direct-acting anti-HBV drugs target the HBV DNA polymerase activity, but the equally essential viral ribonuclease H (RNaseH) activity is unexploited as a drug target. Previously, we reported that α-hydroxytropolone compounds can inhibit the HBV RNaseH and block viral replication. Subsequently, we found that our biochemical RNaseH assay underreports efficacy of the α-hydroxytropolones against HBV replication. Therefore, we conducted a structure-activity analysis of 59 troponoids against HBV replication in cell culture...
June 17, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28633988/a-cross-clade-h5n1-influenza-a-virus-neutralizing-monoclonal-antibody-binds-to-a-novel-epitope-within-the-vestigial-esterase-domain-of-hemagglutinin
#3
Subha Sankar Paul, Chee-Keng Mok, Tze-Minn Mak, Oi-Wing Ng, James Odame Aboagye, Teddy John Wohlbold, Florian Krammer, Yee-Joo Tan
The sporadic outbreaks of highly pathogenic H5N1 avian influenza virus have raised public health concerns. Monoclonal antibodies (MAbs) against hemagglutinin (HA) have been increasingly used successfully for therapeutic purposes. Previously, MAb 9F4, generated against clade 1 H5N1 HA, was observed to have cross-clade neutralizing efficacy and inhibited viral entry by preventing the pH-mediated conformational change of HA. Furthermore, mouse-human chimeric MAb 9F4 was found to retain high degrees of neutralizing activity...
June 17, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28629988/4-azidocytidine-r1479-inhibits-henipaviruses-and-other-paramyxoviruses-with-high-potency
#4
Anne L Hotard, Biao He, Stuart T Nichol, Christina F Spiropoulou, Michael K Lo
The henipaviruses Nipah virus and Hendra virus are highly pathogenic zoonotic paramyxoviruses which have caused fatal outbreaks of encephalitis and respiratory disease in humans. Despite the availability of a licensed equine Hendra virus vaccine and a neutralizing monoclonal antibody shown to be efficacious against henipavirus infections in non-human primates, there remains no approved therapeutics or vaccines for human use. To explore the possibility of developing small-molecule nucleoside inhibitors against henipaviruses, we evaluated the antiviral activity of 4'-azidocytidine (R1479), a drug previously identified to inhibit flaviviruses, against henipaviruses along with other representative members of the family Paramyxoviridae...
June 17, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28629987/anti-herpes-simplex-virus-type-1-activity-of-houttuynoid-a-a-new-flavonoid-from-houttuynia-cordata-thunb
#5
Ting Li, Libao Liu, Hongling Wu, Shaodan Chen, Qinchang Zhu, Hao Gao, Xiongtao Yu, Yi Wang, Wenhan Su, Xinsheng Yao, Tao Peng
Early events in herpes simplex virus type 1 (HSV-1) infection reactivate latent human immunodeficiency virus, Epstein-Barr virus, and human papillomavirus in the presence of acyclovir (ACV). The common use of nucleoside analog medications, such as ACV and pencyclovir, has resulted in the emergence of drug-resistant HSV-1 strains in clinical therapy. Therefore, new antiherpetics that can inhibit early events in HSV-1 infection should be developed. An example of this treatment is Houttuynia cordata Thunb. water extract, which can inhibit HSV-1 infection through multiple mechanisms...
June 16, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28629986/identification-of-influenza-polymerase-inhibitors-targeting-polymerase-pb2-cap-binding-domain-through-virtual-screening
#6
Ming Liu, Edwin Chun-Yeung Lo, Guoxin Wang, Hak-Fun Chow, Jacky Chi-Ki Ngo, David Chi-Cheong Wan, Leo Lit-Man Poon, Pang-Chui Shaw
Influenza A virus is the major cause of epidemics and pandemics worldwide. In this study, virtual screening was used to identify compounds interacting with influenza A polymerase PB2 cap-binding domain (CBD). With a database of 21,351 small molecules, 28 candidate compounds were obtained and four of them (225, 225D1, 426 and 426Br) were found to bind directly to PB2 CBD by surface plasmon resonance (SPR). The evaluation of compounds 426Br and 225 indicated that they could bind to PB2 CBD and inhibit influenza virus at low micromolar concentration...
June 16, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28625478/a-neonatal-mouse-model-of-coxsackievirus-a10-infection-for-anti-viral-evaluation
#7
Shuxuan Li, Huan Zhao, Lisheng Yang, Wangheng Hou, Longfa Xu, Yangtao Wu, Wei Wang, Chunye Chen, Junkai Wan, Xiangzhong Ye, Zhenglun Liang, Qunying Mao, Tong Cheng, Ningshao Xia
Epidemiological data indicate that coxsackievirus A10 (CVA10) has become one of the main causative agents of hand, foot and mouth disease (HFMD) and in recent years has often been found to co-circulate with other enteroviruses, which poses a challenge for the prevention and control of HFMD. Although most CVA10-associated HFMD cases present mild symptoms, severe manifestations and even death can also occur. However, the study of the pathogenesis and the development of drugs and vaccines for CVA10 infection is still far from complete...
June 15, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28624460/identification-of-kx2-391-as-an-inhibitor-of-hbv-transcription-by-a-recombinant-hbv-based-screening-assay
#8
Keisuke Harada, Hironori Nishitsuji, Saneyuki Ujino, Kunitada Shimotohno
Antiviral therapies for chronic hepatitis B virus (HBV) infection that are currently applicable for clinical use are limited to nucleos(t)ide analogs targeting HBV polymerase activity and pegylated interferon alpha (PEG-IFN). Towards establishing an effective therapy for HBV related diseases, it is important to develop a new anti-HBV agent that suppresses and eradicates HBV. This study used recombinant HBV encoding NanoLuc to screen anti-HBV compounds from 1827 US Food and Drug Administration approved compounds and identified several compounds that suppressed HBV infection...
June 15, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28624462/evaluation-on-antiviral-activity-of-coumarin-derivatives-against-spring-viraemia-of-carp-virus-in-epithelioma-papulosum-cyprini-cells
#9
Lei Liu, Yang Hu, Yu-Feng Shen, Gao-Xue Wang
As one of the most serious pathogens in the freshwater aquatic environment, spring viraemia of carp virus (SVCV) can induce a high mortality rate in several cyprinid fishes. In this study, we designed and synthesized a total of 44 coumarin derivatives to evaluate the anti-SVCV activity. By comparing the inhibitory concentration at half-maximal activity (IC50), two imidazole coumarins (B4 and C2) were selected, with maximum inhibitory rates on SVCV more than 90%. Mechanistically, B4 or C2 did not affect viral adhesion and delivery from endosomes to the cytosol...
June 14, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28624461/emetine-inhibits-replication-of-rna-and-dna-viruses-without-generating-drug-resistant-virus-variants
#10
Nitin Khandelwal, Yogesh Chander, Thachamvally Riyesh, Krishan Dutt Rawat, Pratibha Saini, Chikkahonnaiah Nishanth, Shalini Sharma, Naresh Jindal, Bhupendra N Tripathi, Sanjay Barua, Naveen Kumar
At a noncytotoxic concentration, emetine was found to inhibit replication of DNA viruses [buffalopoxvirus (BPXV) and bovine herpesvirus 1 (BHV-1)] as well as RNA viruses [peste des petits ruminants virus (PPRV) and Newcastle disease virus (NDV)]. Using the time-of-addition and virus step-specific assays, we showed that emetine treatment resulted in reduced synthesis of viral RNA (PPRV and NDV) and DNA (BPXV and BHV-1) as well as inhibiting viral entry (NDV and BHV-1). In addition, emetine treatment also resulted in decreased synthesis of viral proteins...
June 14, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28619679/antiviral-activity-of-1-2-3-triazolo-4-5-d-pyrimidin-7-6h-ones-against-chikungunya-virus-targeting-the-viral-capping-nsp1
#11
Alba Gigante, Asier Gómez-SanJuan, Leen Delang, C Li, Oskía Bueno, Ana María Gamo, Eva-María Priego, María-José Camarasa, Dirk Jochmans, Pieter Leyssen, Etienne Decroly, Bruno Coutard, Gilles Querat, Johan Neyts, María-Jesús Pérez-Pérez
Chikungunya virus (CHIKV) is a re-emerging alphavirus transmitted to humans by Aedes mosquitoes. Since 2005, CHIKV has been spreading worldwide resulting in epidemics in Africa, the Indian Ocean islands, Asia and more recently in the Americas. CHIKV is thus considered as a global health concern. There is no specific vaccine or drug available for the treatment of this incapacitating viral infection. We previously identified 3-aryl-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones as selective inhibitors of CHIKV replication and proposed the viral capping enzyme nsP1 as a target...
June 12, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28619678/april-taci-axis-is-dispensable-for-the-immune-response-to-rabies-vaccination
#12
Shannon L Haley, Evgeni P Tzvetkov, Andrew G Lytle, Kishore R Alugupalli, Joseph R Plummer, James P McGettigan
There is significant need to develop a single-dose rabies vaccine to replace the current multi-dose rabies vaccine regimen and eliminate the requirement for rabies immune globulin in post-exposure settings. To accomplish this goal, rabies virus (RABV)-based vaccines must rapidly activate B cells to secrete antibodies which neutralize pathogenic RABV before it enters the CNS. Increased understanding of how B cells effectively respond to RABV-based vaccines may improve efforts to simplify post-exposure prophylaxis (PEP) regimens...
June 12, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28595824/zika-in-the-americas-year-2-what-have-we-learned-what-gaps-remain-a-report-from-the-global-virus-network
#13
REVIEW
Matthew T Aliota, Leda Bassit, Shelton S Bradrick, Bryan Cox, Mariano A Garcia-Blanco, Christina Gavegnano, Thomas C Friedrich, Thaddeus G Golos, Diane E Griffin, Andrew Haddow, Esper G Kallas, Uriel Kitron, Marc Lecuit, Diogo M Magnani, Caroline Marrs, Natalia Mercer, Edward McSweegan, Lisa Ng, David H O'Connor, Jorge E Osorio, Guilherme S Ribeiro, Michael Ricciardi, Shannan L Rossi, George Saade, Raymond F Schinazi, Geraldine O Schott-Lerner, Chao Shan, Pei-Yong Shi, David I Watkins, Nikos Vasilakis, Scott C Weaver
In response to the outbreak of Zika virus (ZIKV) infection in the Western Hemisphere and the recognition of a causal association with fetal malformations, the Global Virus Network (GVN) assembled an international taskforce of virologists to promote basic research, recommend public health measures and encourage the rapid development of vaccines, antiviral therapies and new diagnostic tests. In this article, taskforce members and other experts review what has been learned about ZIKV disease in humans, its modes of transmission and the cause and nature of associated congenital manifestations...
June 5, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28583475/ubiquitin-c-terminal-hydrolase-l3-promotes-interferon-antiviral-activity-by-stabilizing-type-i-interferon-receptor
#14
Peng Zhao, Tingting Guo, Liping Qian, Xiaofang Wang, Yukang Yuan, Qiao Cheng, Yibo Zuo, Jin Liu, Ying Miao, Qian Feng, Liting Zhang, Shuhua Wu, Hui Zheng
Type-I interferons (IFN-I) are important antiviral drugs which are widely used in clinical therapy of diverse viral infections. However, understanding the detailed mechanisms for IFN-I antiviral signaling remains a major challenge, and may provide novel targets for IFN-based antiviral therapy. So far, the roles of deubiquitinases (DUBs) in regulating IFN-I antiviral activity are still largely unexplored. Here, we find that Ubiquitin C-terminal hydrolase-L3 (UCHL3) plays an important role in regulating type I-interferon (IFN-I) mediated antiviral response...
June 3, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28579441/the-role-of-ticks-in-the-maintenance-and-transmission-of-crimean-congo-hemorrhagic-fever-virus-a-review-of-published-field-and-laboratory-studies
#15
REVIEW
Aysen Gargili, Agustin Estrada-Peña, Jessica R Spengler, Alexander Lukashev, Patricia A Nuttall, Dennis A Bente
This manuscript is part of a series of reviews that aim to cover published research on Crimean-Congo hemorrhagic fever (CCHF) and its etiological agent, CCHF virus (CCHFV). The virus is maintained and transmitted in a vertical and horizontal transmission cycle involving a variety of wild and domestic vertebrate species that act as amplification hosts, without showing signs of illness. These vertebrates have traditionally been considered reservoirs of CCHFV, but in fact they develop only a transient viremia, while the virus can persist in ticks for their entire lifespan, and can also be transmitted vertically to the next generation...
June 1, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28549970/distinct-patterns-of-cellular-immune-response-elicited-by-influenza-non-adjuvanted-and-as03-adjuvanted-monovalent-h1n1-pdm09-vaccine
#16
Sarah Giarola-Silva, Jordana G A Coelho-Dos-Reis, Marina Moraes Mourão, Ana Carolina Campi-Azevedo, Erick E Nakagaki Silva, Maria Luiza-Silva, Marina Angela Martins, Amanda Cardoso de Oliveira Silveira-Cassette, Maurício Azevedo Batista, Vanessa Peruhype-Magalhães, Lis Ribeiro do Valle do Valle Antonelli, José Geraldo Leite Ribeiro, Silvana Maria Elói-Santos, Alexandre Vieira Machado, Andréa Teixeira-Carvalho, Olindo Assis Martins-Filho, Márcio Sobreira Silva Araújo
The study aimed at identifying biomarkers of immune response elicited by non-adjuvanted-(NAV) and adjuvanted-(AV) H1N1(pdm09) vaccines. The results showed that despite both vaccines elicited similar levels of anti-H1N1 antibodies at day30 after vaccination, higher reactivity was observed in AV at day180. While AV induced early changes in cell-surface molecules on monocytes, CD4(+), CD8(+) T-cells and B-cells, NAV triggered minor changes, starting later on at day3. Furthermore, AV induced a late and persistent increase in TLR gene expression after day3, except for tlr4, while NAV displayed earlier but transient tlr3/4/7/9 up-regulation...
May 23, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28535933/anti-inflammatory-effects-of-adjunctive-macrolide-treatment-in-adults-hospitalized-with-influenza-a-randomized-controlled-trial
#17
Nelson Lee, Chun-Kwok Wong, Martin C W Chan, Esther S L Yeung, Wilson W S Tam, Owen T Y Tsang, Kin-Wing Choi, Paul K S Chan, Angela Kwok, Grace C Y Lui, Wai-Shing Leung, Irene M H Yung, Rity Y K Wong, Catherine S K Cheung, David S C Hui
INTRODUCTION: - Macrolides can ameliorate inflammation in respiratory diseases, providing clinical benefits. Data in influenza is lacking. METHOD: - A randomized, open-label, multicenter trial among adults hospitalized for laboratory-confirmed influenza was conducted. Study treatments of oseltamivir and azithromycin (500 mg/day), or oseltamivir alone, both for 5 days, were allocated at 1:1 ratio. The primary outcome was plasma cytokine/chemokine concentration change over time (Day 0-10); secondary outcomes were viral load and symptom score changes...
May 20, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28529001/a-single-intranasal-administration-of-virus-like-particle-vaccine-induces-an-efficient-protection-for-mice-against-human-respiratory-syncytial-virus
#18
Yue-Ying Jiao, Yuan-Hui Fu, Yi-Fei Yan, Ying Hua, Yao Ma, Xiu-Juan Zhang, Jing-Dong Song, Xiang-Lei Peng, Jiaqiang Huang, Tao Hong, Jin-Sheng He
Human respiratory syncytial virus (RSV) is an important pediatric pathogen causing acute viral respiratory disease in infants and young children. However, no licensed vaccines are currently available. Virus-like particles (VLPs) may bring new hope to producing RSV VLP vaccine with high immunogenicity and safety. Here, we constructed the recombinants of matrix protein (M) and fusion glycoprotein (F) of RSV, respectively into a replication-deficient first-generation adenoviral vector (FGAd), which were used to co-infect Vero cells to assemble RSV VLPs successfully...
May 18, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28529000/preclinical-evaluation-of-vis513-a-therapeutic-antibody-against-dengue-virus-in-non-human-primates
#19
Eugenia Z Ong, Yadunanda Budigi, Hwee Cheng Tan, Luke N Robinson, Kirk J Rowley, Alexander Winnett, Sven Hobbie, Zachary Shriver, Gregory J Babcock, Eng Eong Ooi
Despite useful in vivo activity, no therapeutic against dengue virus (DENV) has demonstrated efficacy in clinical trials. Herein, we explored dosing and virological endpoints to guide the design of human trials of VIS513, a pan-serotype anti-DENV IgG1 antibody, in non-human primates (NHPs). Dosing VIS513 pre- or post-peak viremia in NHPs neutralized infectious DENV although RNAemia remained detectable post-treatment; differential interaction of human IgGs with macaque Fc-gamma receptors may delay clearance of neutralized DENV...
May 18, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28511994/study-of-rubella-candidate-vaccine-based-on-a-structurally-modified-plant-virus
#20
Ekaterina A Trifonova, Vladimir A Zenin, Nikolai A Nikitin, Maria S Yurkova, Ekaterina M Ryabchevskaya, Egor V Putlyaev, Ekaterina K Donchenko, Olga A Kondakova, Alexey N Fedorov, Joseph G Atabekov, Olga V Karpova
A novel rubella candidate vaccine based on a structurally modified plant virus - spherical particles (SPs) - was developed. SPs generated by the thermal remodelling of the tobacco mosaic virus are promising platforms for the development of vaccines. SPs combine unique properties: biosafety, stability, high immunogenicity and the effective adsorption of antigens. We assembled in vitro and characterised complexes (candidate vaccine) based on SPs and the rubella virus recombinant antigen. The candidate vaccine induced a strong humoral immune response against rubella...
May 13, 2017: Antiviral Research
journal
journal
28222
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"